UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 10, 2016

DLH Holdings Corp. (Exact name of registrant as specified in its charter)

COMMISSION FILE NUMBER: 0-18492

New Jersey

22-1899798

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

3565 Piedmont Road, NE, Bldg. 3, Suite 700 Atlanta, GA 30305

(Address and zip code of principal executive offices)

(866) 952-1647

(Registrant's telephone number, including area code)

CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:

| ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|----------------------------------------------------------------------------------------------------------|
| ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Item 7.01 Regulation FD Disclosure

On August 2, 2016, DLH Holdings Corp. ("DLH") announced its participation in the Canaccord Genuity 36th Annual Growth Conference in Boston, Massachusetts on August 10, 2016 at 12:30 p.m., eastern time. At the conference, DLH's management intends to discuss the information described in the presentation materials attached to this Current Report as Exhibit 99.1. A copy of DLH's presentation materials will also be available on DLH's website under the "Presentations" tab on the investor relations page at http://www.dlhcorp.com/investor-relations.aspx.

The slide presentation furnished as Exhibit 99.1 to this Current Report includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are "forward-looking" rather than historical.

The information in this Current Report shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) The following exhibit is attached to this Current Report on Form 8-K:

Exhibit

Number Exhibit Title or Description

99.1 Presentation Materials of DLH Holdings Corp. to be discussed on August 10, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

DLH Holdings Corp.

By: /s/ Kathryn M. JohnBull

Name: Kathryn M. JohnBull Title: Chief Financial Officer

Date: August 10, 2016

EXHIBIT INDEX

Exhibit

Number Exhibit Title or Description

99.1 Presentation Materials of DLH Holdings Corp. to be discussed on August 10, 2016



ntegrity & Trust | Performance Excellence | Inclusion & Diversity | Agilit

Forward Looking Statement

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH's future financial performance. Any statements that are not statements of historical fact (including without limitation statements to the effect that the Company or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially from those indicated by the forward-looking statements. For a discussion of such risks and uncertainties, see "Risk Factors" in the company's periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2015. In light of the risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. The forward-looking statements contained in this presentation are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating any forward-looking statements.

This presentation contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. These measures should be used in conjunction with, rather than instead of, their comparable GAAP measures. A reconciliation of non-GAAP measures to the comparable GAAP measures presented in this document is contained at the end of this presentation and in the Company's most quarterly earnings press releases for the relevant periods indicated in this presentation.



Investor Highlights

- "Pure Play" government services provider
- Leading position in growing healthcare markets, with long-term contracts at attractive federal agencies
 - VA, DoD, HHS, CDC
- Completed transformational acquisition of Danya
 - Brings leading contract vehicles, strong margins
 - Increases Company revenue base by 50% and aligns with core end markets
- Strong cash flow and improving balance sheet
- Disciplined management has overhauled company
- Well positioned for higher growth and financial performance going forward







Who We Are & What We Do

Primary DLH Markets and Offerings



Health Services for Active Duty Military and Veterans

Human Services & Solutions Public Health and Life Sciences





- Clinical device research and development
- Medication Therapy Management (pharma)
- Access to care (Behavioral and Medications)
- Case management tools and services

- Lifecycle management of medical devices
- Analytics and decision support systems
- Supply chain and inventory management











DLH Has Dramatically Changed in Six Years

FY2010-2012: Changed Corporate Leadership


FY2011: Long Range Strategic Plan (LRSP) Developed

FY2012: Create Stability and Backlog

FY2013: Project L.E.A.N. Cost Realignment

FY2014-15: Financial Health and Business Development

FY2016: Technology leverage and Acquisition of Danya



(1) A reconciliation of third quarter fiscal 2016 Adjusted EBITDA, a non-GAAP measure, can be found at the end of this presentation. Historical information can be found in the quarterly and annual reports filed with the Securities and Exchange Commission, located on the Company website at www.dlhcorp.com/sec-filings.aspx,



Transformative Acquisition: Danya – May 2016

Highly complementary businesses with common core capabilities for complex, nationally dispersed programs, operational synergies, and new business opportunities

Portfolio Diversification

- Expands DLH's market opportunity and diversifies its portfolio of healthcare and human services contracts and programs to four top federal agencies
 - Department of Veterans Affairs ("VA")
 - Department of Health and Human Services ("HHS")
 - Department of Defense ("DoD")
 - Centers for Disease Control and Prevention ("CDC")

Deep Domain Expertise


 Recognized professional subject matter experts and management teams tackling critical long-term national issues and trends in public health, healthcare delivery, systems migrations, and compliance monitoring

Corporate Culture

- Common set of values delivered to customers and throughout the workforce:
 - Integrity & Trust
 - Inclusion & Diversity




LTM Trading Performance Relative to Industry (1)




Danya's Markets & Capabilities

- Danya's flagship prime contract with HHS' Office of Head Start ("OHS") aligns with DLH's capabilities and solutions that impact diverse communities and populations
- DLH expects to integrate components of its capabilities to deliver tailored solutions for customers in health IT, pharmacy medication adherence & compliance, telehealth, and medical service delivery
- With Danya, DLH will to continue to drive innovative solutions and ensure program success through strategy development and effective management



DLH Broad Healthcare Delivery Solutions





Breadth and Depth in Pharmacy

Coverage ranging from single clinic to operating in high-volume automated prescription production and distribution system environments.



- Virtual / Tele-pharmacy services
- Pharmacy systems automation (including robotics), implementation, and testing
- Bio-hazards management; Med/Surg systems and equipment
- Cold storage systems; Specialty-meds
- Controlled substance management
- Prescription servicing and Quality Assurance (outpatient and in-patient)
- Medical warehouse supply chain management



Differentiation in Process & Technology

DLH delivers high-value performance in partnership with and in support of customers, teams, and end-users as measured by....



DLH's ePRAT provides a web-based, open-architecture, secure system to *manage expert delivery* and *resourcing* of the "*continuum of care requirements*" for combatants, veterans, and retirees. Designed to meet HIPAA, CCAC, CARF, FISMA, NIST requirements




DLH's unique approach to integration of people, processes, and technology tools to *measure*, *manage* and *optimize* our performance at project or enterprise levels.



Federal Health Markets Attractive for Growth

Federal Health Expenditure Projections




National health spending expected to reach \$5.63 trillion and comprise 20.1% of GDP by 2025

Federal portion expected to grow at a 4.9% CAGR, reaching \$1.75 trillion by 2025



Buying Behavior: FY2015 HHS Spending




0 \$500,000 \$1,000,000 \$1,500,000 \$2,000,000 \$2,500,000 \$3,000,000 \$3,500,000 \$4,500,000 \$4,500,000 \$5,000,000 \$5,500,000 \$6,000,000 \$6,500,000 Spending to Date (\$K)

Source: Federal Procurement Data System, GovWin IQ



Buying Behavior: FY2015 Contract Vehicle



\$0 \$50,000 \$100,000 \$150,000 \$200,000 \$250,000 \$300,000 \$350,000 \$400,000 \$450,000 \$550,000 \$650,000 \$650,000 \$750,000 \$750,000 \$800,000 \$850,000 \$990,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$

Source: Federal Procurement Data System, GovWin IQ





Leverage outstanding performance track record that has resulted JD Power award for Veterans Affairs client to expand within the VA and adjacent federal health oriented markets (including DoD)

Focus growth where government decision makers prioritize "best value" over "lowest and cheapest price"

Shape new business pursuits around greater complexity work requirements which typically yield higher gross margins

Use dramatically improved company financial health posture to add appropriately scaled acquisition to the DLH playbook

KEYS

STRATEGIC MODEL

DRIVE PRFORMANCE EXCELLENCE

Build upon current market leading customer satisfaction

Instill continuous improvement culture throughout operations

BUILD UPON CURRENT DIFFERENTIATORS

Accelerate technology refresh cycle time

Prioritize healthcare COTS solutions where feasible

BUILD POWERHOUSE MARKETING POSITION

Deliver strategically aligned and robust "Qualified NB Pipeline"

Expand and align business development resources

DEPLOY CAPITAL FOR GROWTH

PLAYBOOK

Make acquisitions consistent with growth strategy

Solidify financing capacity

Ensure adequate and scaled "Deal Flow"

NAVIGATE POLITICAL **ENVIRONMENT ISSUES**

Increase connectivity to market "Shapers"

Engage trade associations & capital market affiliations

Align composition of board of directors to fit

Organic Growth ->







Acquisitions → Margin Expansion → Shareholder Value






Recent Results - QTR Ended 6/30/16









* A reconciliation of Adjusted EBITDA, a non-GAAP measure, can be found at the end of this presentation.

Liquidity - 6/30/2016

Gaining Strength Post Acquisition



Cash on Hand



Revolving Credit Facility

Paid off \$5.0M Acq. Loan

\$0.8M loan balance tied to operational cash flow



Term Loan \$24.7M Balance

Plan to accelerate principal payments with cash from profitable operations



Investor Highlights

- "Pure Play" government services provider
- Leading position in growing healthcare markets, with long-term contracts at attractive federal agencies
 - VA, DoD, HHS, CDC
- Completed transformational acquisition of Danya
 - Brings leading contract vehicles, strong margins
 - Increases Company revenue base by 50% and aligns with core end markets
- Strong cash flow and improving balance sheet
- Disciplined management has overhauled company
- Well positioned for higher growth and financial performance going forward











Backup Slides

Integrity & Trust | Performance Excellence | Inclusion & Diversity | Agility

45

FY16 YTD Year over Year — 9 months ended 6/30/16









* A reconciliation of Adjusted EBITDA, a non-GAAP measure, can be found at the end of this presentation.

Cash Flows for Nine Months Ended 6/30/16

Financed Danya Acquisition on 5/3/16

| \$5,558 \$3,380 |
|--------------------|
| \$3,380 |
| |
| (32,278) |
| 26,610 |
| \$2,820 |
| |



F3Q16 Financials

| | (unaudited) | | | (unaudited) | | | | | | |
|--------------------------------------------|--------------------|--------|------|-------------------|----|---------|----|--------|--|--|
| | Three Months Ended | | | Nine Months Ended | | | | | | |
| | June 30, | | | | | ne 30, | | | | |
| | _ | 2016 | 1000 | 2015 | | 2016 | - | 2015 | | |
| Revenue | \$ | 24,989 | \$ | 16,781 | \$ | 58,482 | \$ | 48,357 | | |
| Direct expenses | | 19,533 | | 13,743 | | 46,885 | | 40,055 | | |
| Gross margin | | 5,456 | | 3,038 | | 11,597 | | 8,302 | | |
| General and administrative expenses | | 3,374 | | 2,270 | | 8,402 | | 6,719 | | |
| Depreciation and amortization expense | | 414 | | 5 | | 456 | | 45 | | |
| Income from operations | | 1,668 | 6/2 | 763 | | 2,739 | | 1,538 | | |
| Total other income (expense), net | | (374) | | (34) | | (1,076) | | (723) | | |
| Income before income taxes | | 1,294 | | 729 | | 1,663 | | 815 | | |
| Income tax expense(benefit) | | 518 | | 292 | | 666 | | 326 | | |
| Net income | \$ | 776 | \$ | 437 | \$ | 997 | \$ | 489 | | |
| Net income per share - basic | \$ | 0.08 | \$ | 0.05 | \$ | 0.10 | \$ | 0.05 | | |
| Net income per share - diluted | \$ | 0.07 | \$ | 0.04 | \$ | 0.09 | \$ | 0.05 | | |
| Weighted average common shares outstanding | | | | | | | | | | |
| Basic | | 10,154 | | 9,552 | | 9,812 | | 9,580 | | |
| Diluted | | 11,311 | | 9,956 | | 10,855 | | 9,990 | | |
| Diluted | | 11,311 | | 9,956 | | 10,855 | | 9,990 | | |



F3Q16 Adjusted EBITDA Reconciliation(1)

| | Three Months Ended June 30, | | | Nine Months End June 30, | | | | aded | ided | | | |
|---------------------------------------------------|--------------------------------|-------|----|-----------------------------|----|--------|----|--------|------|-------|----|-------|
| | | 2016 | | 2015 | (| Change | | 2016 | | 2015 | | hange |
| Net income | \$ | 776 | \$ | 437 | \$ | 339 | \$ | 997 | \$ | 489 | \$ | 508 |
| (i) Interest and other (income) expense (net): | | | | | | | | | | | | |
| (i)(a) Interest and other expense | | 281 | | 34 | | 247 | | 281 | | 723 | | (442) |
| (i)(b) Acquisition expenses | | 93 | | _ | | 93 | | 795 | | _ | | 795 |
| (ii) Provision (benefit) for taxes | | 518 | | 292 | | 226 | | 666 | | 326 | | 340 |
| (iii) Depreciation and amortization | | 414 | | 5 | | 409 | | 456 | | 45 | | 411 |
| (iv) G&A expenses - equity grants | | 42 | | 72 | | (30) | | 384 | | 418 | | (34) |
| Adjusted EBITDA | \$ 2 | 2,124 | \$ | 840 | \$ | 1,284 | \$ | 3,579 | \$ | 2,001 | \$ | 1,578 |
| Weighted-average outstanding shares fully diluted | 1 | 1,311 | 9 | ,956 | | 1,355 | | 10,855 | | 9,990 | | 865 |

⁽¹⁾ For a further explanation of Adjusted EBITDA, a non-GAAP measure, please refer to the Company's most recent quarterly and annual reports filed with the Securities and Exchange Commission, which can be found on the DLH website at: www.dlhcorp.com/news-releases.aspx and/or www.dlhcorp.com/sec-filings.aspx.





Corporate Headquarters: 3565 Piedmont Rd NE Building 3, Suite 700 Atlanta, GA 30305 National Capital Region Office: 8737 Colesville Road Suite 1100 Silver Spring, MD 20910



24 © 2016 | DLH | Proprietary